For instance, the SURMOUNT-OSA trial found that tirzepatide significantly reduced plasma levels of C-reactive protein, a marker associated with systemic low-grade inflammation and cardiovascular disease (Malhotra et al., 2024). The gene discussed is CRP; the disease is obstructive sleep apnea syndrome.